Literature DB >> 29685457

Drug-resistant tuberculosis: the rise of the monos.

Ebrahim Variava1, Neil Martinson2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29685457     DOI: 10.1016/S1473-3099(18)30247-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.

Authors:  Clarisse A Tsang; Neha Shah; Lori R Armstrong; Suzanne M Marks
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

2.  Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey.

Authors:  Collins Timire; John Z Metcalfe; Joconiah Chirenda; Jerod N Scholten; Barbara Manyame-Murwira; Mkhokheli Ngwenya; Ronnie Matambo; Kelvin Charambira; Herbert Mutunzi; Nico Kalisvaart; Charles Sandy
Journal:  Int J Infect Dis       Date:  2019-07-27       Impact factor: 12.074

Review 3.  Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.

Authors:  Vaishali P Waman; Sundeep Chaitanya Vedithi; Sherine E Thomas; Bridget P Bannerman; Asma Munir; Marcin J Skwark; Sony Malhotra; Tom L Blundell
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

Review 4.  Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management.

Authors:  Dale Liebenberg; Bhavna Gowan Gordhan; Bavesh Davandra Kana
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

5.  Effects of secondary infections on the multidrug-resistant Tuberculosis: A cohort study.

Authors:  Nurlan Tabriz; Zhanara B Nurtazina; Margulan T Kozhamuratov; Kuliya Skak; Zhumat Mutaikhan
Journal:  Med J Islam Repub Iran       Date:  2021-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.